News & Updates
Filter by Specialty:
New COVID-19 campaign highlights speed in testing, treating
The Malaysian Society of Infection Control and Infectious Diseases (MyICID) in collaboration with Family Medicine Association Malaysia (FMSA) and Malaysian Medical Association (MMA) have launched an educational campaign themed ‘COVID-19: Quickly test and treat.’
New COVID-19 campaign highlights speed in testing, treating
23 Jul 2024
![[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma](https://sitmspst.blob.core.windows.net/images/articles/angels-and-demons-3cde1853-f09a-4511-a0c7-1794e52dc9d8-square.jpg)
Adalimumab concentrations negatively linked to inflammatory markers in RA
A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.
Adalimumab concentrations negatively linked to inflammatory markers in RA
22 Jul 2024
High CRP level tied to earlier death in ILD
Increased levels of serum C-reactive protein (CRP) may contribute to shorter survival in patients with idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), or systemic sclerosis (SSc)-associated ILD at 5 years.
High CRP level tied to earlier death in ILD
21 Jul 2024
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.